May 15, 2008, KV Pharmaceutical Company , a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets technology-differentiated branded products and generic/non-branded prescription pharmaceuticals, announced today that it has received final approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) to market its 50 mg strength of metoprolol succinate extended-release tablets. The Company expects to begin shipping immediately. This product is a generic version of AstraZeneca's branded product, Toprol-XL(R) and the 50 mg strength recorded total branded and generic dollar volume in 2007 of $585 million according to IMS America. The 50 mg strength is the largest of the four strengths in both units sold and dollar volume.
The details can be read here.
No comments:
Post a Comment